I-MAB (FRA:0VY) Days Sales Outstanding : 0.00 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Days Sales Outstanding?

I-MAB's average Accounts Receivable for the six months ended in Dec. 2023 was €0.00 Mil. I-MAB's Revenue for the six months ended in Dec. 2023 was €1.03 Mil. Hence, I-MAB's Days Sales Outstanding for the six months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for I-MAB's Days Sales Outstanding or its related term are showing as below:

FRA:0VY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.18 Med: 181.5 Max: 332.12
Current: 7.18

During the past 7 years, I-MAB's highest Days Sales Outstanding was 332.12. The lowest was 7.18. And the median was 181.50.

FRA:0VY's Days Sales Outstanding is ranked better than
96.4% of 888 companies
in the Biotechnology industry
Industry Median: 72.665 vs FRA:0VY: 7.18

I-MAB's Days Sales Outstanding stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

I-MAB Days Sales Outstanding Historical Data

The historical data trend for I-MAB's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Days Sales Outstanding Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

30.88

313.36

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial								85.95	58.15	-	-	-

Competitive Comparison of I-MAB's Days Sales Outstanding

For the Biotechnology subindustry, I-MAB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where I-MAB's Days Sales Outstanding falls into.

I-MAB Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

I-MAB's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	3.55	*	365
=	0					/	3.55	*	365
=	0.00

I-MAB's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	1.026	*	365 / 2
=	0					/	1.026	*	365 / 2
=	0.00

I-MAB (FRA:0VY) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

I-MAB Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of I-MAB's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (FRA:0VY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (FRA:0VY) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

IMAB:USA

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.

I-MAB (FRA:0VY) Headlines

No Headlines